Online citations, reference lists, and bibliographies.
← Back to Search

Microsomal Catalyzed N-hydroxylation Of Guanabenz And Reduction Of The N-hydroxylated Metabolite: Characterization Of The Two Reactions And Genotoxic Potential Of Guanoxabenz.

B. Clement, M. Demesmaeker, S. Linne
Published 1996 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The N-reduction of the centrally acting alpha 2-adrenoreceptor agonist guanoxabenz (Benzérial), an N-hydroxyamidinohydrazone, to the amidinohydrazone guanabenz (Wytensin, Hipten, Rexitene) by microsomal fractions from rabbits, pigs and humans has been detected in vitro. The conversion rates with rabbit microsomal fractions were markedly slower than those in the cases of fractions from humans and pigs. It was also possible to demonstrate the N-oxidation of guanabenz to guanoxabenz by the use of microsomal fractions from rabbits, pigs, and humans. Furthermore, the oxidation was also observed in reconstituted systems in the presence of enriched cytochrome P450 fractions, purified isoenzyme P450 2C3, and heterologously expressed P450 2C3 of the subforms 6 beta H and 6 beta L. The analyses were performed with a newly developed HPLC technique and were confirmed by LC-MS methods. The kinetic parameters determined for the metabolic cycle (bioreversible reactions) are indicative of a predominance of the reduction of guanoxabenz to guanabenz in vivo. Accordingly, guanoxabenz in part constitutes a prodrug of guanabenz. Examination of guanabenz and guanoxabenz for mutagenicity by means of the Ames test revealed that guanoxabenz has pronounced mutagenic effects in the strains TA 98 and TA 1537. Guanabenz did not exhibit mutagenicity so that the N-reduction of guanoxabenz has significance in terms of detoxification.



This paper is referenced by
10.3390/molecules22091394
Development and Validation of HPLC-DAD and UHPLC-DAD Methods for the Simultaneous Determination of Guanylhydrazone Derivatives Employing a Factorial Design
Wanessa Azevedo de Brito (2017)
10.1016/j.pharmthera.2010.02.005
Modulating the NO generating system from a medicinal chemistry perspective: current trends and therapeutic options in cardiovascular disease.
D. Schade (2010)
10.1002/ARDP.19973300907
Microsomal Catalyzed N‐Hydroxylation of Guanfacine and Reduction of N‐Hydroxyguanfacine
B. Clement (1997)
10.1074/jbc.272.31.19615
Isolation and Characterization of the Protein Components of the Liver Microsomal O2-insensitive NADH-Benzamidoxime Reductase*
B. Clement (1997)
10.1080/00498250600700496
Metabolism of cytostatically active 6-aminobenzo[c]phenanthridines by human and porcine hepatic microsomes and recombinant cytochrome P450 enzymes
I. Zebothsen (2006)
10.1248/BPB.30.967
Metabolism of FPP-3, an anti-inflammatory propenone compound, in rat by liquid chromatography-electrospray ionization tandem mass spectrometry.
S. Lee (2007)
10.1124/DMD.31.5.645
Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug.
B. Clement (2003)
10.1007/s12272-001-1224-3
In vitro characterization of the enzymes involved in the metabolism of 1-Furan-2-yl-3-pyridin-2-yl-propenone, an anti-inflammatory propenone compound
S. Lee (2008)
10.1111/j.1742-7843.2008.00236.x
Inhibitory effects on cytochrome p450 enzymes of pentamidine and its amidoxime pro-drug.
Anja Bürenheide (2008)
10.1002/cmdc.200900233
The Peptidylglycine α‐Amidating Monooxygenase (PAM): A Novel Prodrug Strategy for Amidoximes and N‐Hydroxyguanidines?
D. Schade (2009)
10.1016/J.LFS.2004.12.028
Reduction of sulfamethoxazole and dapsone hydroxylamines by a microsomal enzyme system purified from pig liver and pig and human liver microsomes.
B. Clement (2005)
10.1080/00498250902998699
Flavin-containing monooxygenase 1-catalysed N,N-dimethylamphetamine N-oxidation
S. Lee (2009)
10.1080/00498250010013908
NADH-dependent reduction of sulphamethoxazole hydroxylamine in dog and human liver microsomes
L. Trepanier (2000)
10.1016/j.drudis.2020.06.004
Oseltamivir analogs with potent anti-influenza virus activity.
S. Kumar (2020)
Substituierte L-Arginin-Derivate als Modulatoren des Stickstoffmonoxid-generierenden Systems
J. Kotthaus (2009)
10.3109/00498250903402266
Metabolism and distribution of two highly potent and selective peptidomimetic inhibitors of matriptase
J. Kotthaus (2010)
10.1016/S0006-2952(98)00136-1
Characterization of the enzymatic activity for biphasic competition by guanoxabenz (1-(2,6-dichlorobenzylidene-amino)-3-hydroxyguanidine) at alpha2-adrenoceptors. II. Description of a xanthine-dependent enzymatic activity in spleen cytosol.
M. Dambrova (1998)
10.1002/jps.24508
Zanamivir Amidoxime- and N-Hydroxyguanidine-Based Prodrug Approaches to Tackle Poor Oral Bioavailability.
D. Schade (2015)
10.1124/dmd.105.005249
HEPATIC, EXTRAHEPATIC, MICROSOMAL, AND MITOCHONDRIAL ACTIVATION OF THE N-HYDROXYLATED PRODRUGS BENZAMIDOXIME, GUANOXABENZ, AND RO 48-3656 ([[1-[(2S)-2-[[4-[(HYDROXYAMINO)IMINOMETHYL]BENZOYL]AMINO]-1-OXOPROPYL]-4-PIPERIDINYL]OXY]-ACETIC ACID)
B. Clement (2005)
10.3390/MOLECULES22091394
Development and Validation of HPLC-DAD and UHPLC-DAD Methods for the Simultaneous Determination of Guanylhydrazone Derivatives Employing a Factorial Design
Wanessa Azevedo de Brito (2017)
Formation of guanoxabenz from guanabenz in human liver. A new metabolic marker for CYP1A2.
B. Clement (1997)
10.1016/J.BCP.2005.10.037
Oxygen-insensitive enzymatic reduction of oximes to imines.
Sabine Heberling (2006)
10.1039/c0ob01117g
Prodrug design for the potent cardiovascular agent Nω-hydroxy-L-arginine (NOHA): synthetic approaches and physicochemical characterization.
D. Schade (2011)
10.1111/J.1600-0773.1998.TB01462.X
Characterization of guanoxabenz reducing activity in rat brain.
M. Dambrova (1998)
10.1016/J.BBRC.2006.08.123
Reduction of Nω-hydroxy-l-arginine to l-arginine by pig liver microsomes, mitochondria, and human liver microsomes
B. Clement (2006)
UNIVERSIDADE FEDERAL DO RIO GRANDE DO NORTE CENTRO DE CIÊNCIAS DA SAÚDE PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS FARMACÊUTICAS DESENVOLVIMENTO E VALIDAÇÃO DE MÉTODOS ANALÍTICOS PARA DETERMINAÇÃO DE DIFERENTES GUANILHIDRAZONAS
Autor Discente (2014)
Utilisation d'hydroxyguanidines
J. Wikberg (1997)
10.1002/cmdc.200700031
Highly Potent and Selective Substrate Analogue Factor Xa Inhibitors Containing D‐Homophenylalanine Analogues as P3 Residue: Part 2
A. Stürzebecher (2007)
10.1007/BF02969282
Identification of 1-furan-2-yl-3-pyridin-2-yl-propenone, an anti-inflammatory agent, and its metabolites in rat liver subcellular fractions
S. Lee (2006)
10.1002/rcm.4747
Simultaneous qualitative and quantitative method using liquid chromatography selected reaction monitoring-triggered quantitation-enhanced data-dependent tandem mass spectrometry for the identification and classification of amphetamine-type stimulant abusers in human urine.
S. Lee (2010)
10.1016/S0378-4347(00)00340-6
Chromatography of guanidino compounds.
T. Hanai (2000)
10.1081/DMR-120005643
REDUCTION OF N-HYDROXYLATED COMPOUNDS: AMIDOXIMES (N-HYDROXYAMIDINES) AS PRO-DRUGS OF AMIDINES
B. Clement (2002)
See more
Semantic Scholar Logo Some data provided by SemanticScholar